CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Akt Inhibitor MK2206 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01604772
NCT01604772Phase 2Completed

A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

National Cancer Institute (NCI)·interventional·Posted May 24, 2012·Updated May 1, 2019

In Brief

A Phase 2 clinical trial evaluating Akt Inhibitor MK2206 and Laboratory Biomarker Analysis for Recurrent Oral Cavity Adenoid Cystic Carcinoma and 8 related conditions. Completed, enrolled 16 participants across 51 sites.

Detailed Summary

This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer). Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2012
Enrollment StartJul 23, 2012
Primary CompletionOct 24, 2013
Study CompletionNov 22, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.1 years ago

Interventions

Akt Inhibitor MK2206drug

Given PO

Laboratory Biomarker Analysisother

Correlative studies